ARTICLE | Product Development
The critical path to COVID-19 therapies
Plotting a path to accelerated COVID-19 therapy development
May 30, 2020 12:02 AM UTC
The path to safe, effective COVID-19 therapies is crowded and poorly marked. There is an urgent need to fast-track a manageable number of therapies, illuminate every step along the route, and create signposts for research, development and manufacturing strategies to maximize the chances of success.
The life sciences community is rising to the challenge. Biopharmaceutical companies and academic teams are scouring their pipelines and lab books for agents that could help COVID-19 patients. Over 500 countermeasures are in progress, and at least 202 are in clinical development, according to BioCentury’s COVID-19 Resource Center. ...